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Crouzon syndrome is one of the most common craniofacial syndromes and is inherited as autosomal dominant with variable
expression. We report an 11 and a half-year-old boy with Crouzon syndrome with severe growth retardation. He had hydrocephalus
since infancy and recently suﬀered from frequent dizziness. His bone age was only 5 years according to the Greulich and Pyle atlas.
Magnetic resonance imaging showed shallow orbits, obstructive hydrocephalus, and cerebellar tonsil herniation. Growth hormone
provocative tests revealed a reduced peak growth hormone response in both insulin and clonidine tests. Severe iron deficiency
anemia was noted at the same time. Molecular analysis identified a common mutation point of Cys278Phe for Crouzon syndrome
in exon IIIa of the fibroblast growth factor receptor 2 (FGFR2) gene. Since growth retardation is not a common feature of Crouzon
syndrome, we reviewed the literature for the incidence of hydrocephalus in Crouzon syndrome and the association with growth
hormone deficiency.
1. Introduction
In 1912, Crouzon described a syndrome that consisted of
brachycephaly, shallow orbits, and maxillary hypoplasia [1].
Since then, craniofacial syndromes have been subcategorized
into over a hundred syndromes based on the severity of
the craniofacial and associated congenital malformations [2].
Crouzon syndrome, along with Apert, Carpenter, Chotzen,
and Pfeiﬀer syndromes, is one of the most common
genetic disorders associated with a craniofacial syndrome.
Other facial deformities in Crouzon syndrome may include
prominent nose, frontal bossing, and ocular proptosis due to
shallow orbits with or without hypertelorism, although age-
related phenotype modifications have been reported [3].
Patients of Crouzon syndrome may occasionally present
with hydrocephalus, seizures, and mental retardation. The
incidence of hydrocephalus in craniosynostosis ranges from
4% to 26% [4, 5]. Nonetheless, short stature with growth
hormone deficiency (GHD) and/or iron deficiency anemia
(IDA) have rarely been reported in the literature. Here we
report a case of Crouzon syndrome with hydrocephalus, also
presenting with severe short stature due to GHD and IDA.
2. Case Report
An 11 and a half-year-old boy visited our out-patient
clinic for frequent dizziness and marked growth retardation.
He was a case of Crouzon syndrome which had been
suspected since infancy. The positive facial features were
brachycephaly, hypoplasia maxilla, severe ocular proptosis
(Hertel’s exophthalmometry measuring 22-23 mm on both
eyes) with hypertelorism, and low-set ears. He had a
3200 gm birth weight and was born to a generally healthy
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Figure 1: Direct sequencing data indicated that this patient carries
the Cys278Phe mutation in the exon IIIa of FGFR2 gene.
mother via NSD at 40 wks’ gestational age. Owing to severe
hydrocephalus and cerebellar tonsil herniation (Chiari I
malformation) revealed by magnetic resonance imaging
(MRI), he had endoscopic third ventriculostomy and shunt
at the age of 13 months. Six months later, he received
frontal advancement and ventricular shunting because of a
progressive increase in ventricular size and rising intracranial
pressure (ICP). His head circumference remained at around
the 50th percentile, but he had frequent respiratory tract
infections during early childhood.
The patient had not been followed up regularly after the
age of 6 years until recently. His chief complaint was frequent
dizziness and marked growth retardation. He was 18.5 kg and
111.2 cm, which represented −3 standard deviation (SD) in
body weight and −5 SD in height of his age. His brother,
who is 4 and a half years older, was 182 cm. His parents
are grossly normal and the mid-parent height is 168 cm. On
admission, his general condition was stable and intelligence
quotient (IQ) around 90. The external genital organ was in
the prepuberal stage. Chromosome analysis was normal in
G-banding karyotype; however, molecular analysis identified
a common mutation point of Cys278Phe in exon IIIa of the
fibroblast growth factor receptor 2 (FGFR2) gene (Figure 1).
His bone age was only 4.5–5 years according to the Greulich
and Pyle atlas (Figure 2), which was a 6.5-7- year delay. Skull
radiography showed a shallow and elongated sella turcica.
MRI revealed obstructive hydrocephalus of both lateral ven-
tricles with an interruption of pituitary stalk, shallow orbits,
and Chiari I malformation. Pituitary height was 5.6 mm in
midsagittal T1-weighted spin-echo MRI (Figure 3), which
was around mean according to Tsunoda’s study [6]. A
biochemistry profile revealed thyroid hormones and cortisol
within normal limits, but blood routine showed microcytic
anemia. A growth hormone provocative test revealed a
reduced peak growth hormone response of 4.57 uIU/mL in
the insulin test and 2.63 uIU/mL in the clonidine test. The
concentrations of insulin-like growth factor 1 (IGF-I) and
insulin-like growth factor binding protein 3 (IGF-BP3) were
also very low (IGF-I < 10.0 ng/mL, IGFBP-3 : 1.5µg/mL).
Severe iron deficiency anemia without thalassemia was
noted (hemoglobin: 8.8 g/dL, RBC: 4.18 million/ul, MCV:
R
Figure 2: The patient’s bone age was only 4.5-5 years according to
the Greulich and Pyle atlas.
68.2 fL; serum iron: 7 mg/dL, ferritin: 4 ng/mL, UIBC:
525 mg/dL) with regards to the microcytic anemia. Iron
supplements at a dose of 100 mg/day were subscribed imme-
diately. Human growth hormone (HGH) subcutaneous
replacement at a dose of 0.3 mg/kg/week in seven divided
doses was also subscribed, and the growth velocity was 3 cm
per year during the first half year. After his hemoglobin and
serum iron levels gradually returned to normal, his dizziness
disappeared and his growth velocity increased to 5 cm per
year under HGH therapy.
3. Discussion
We reviewed the literature for the incidence of hydrocephalus
in Crouzon syndrome and the association with GHD, only
one case report: “Crouzon syndrome with short stature due to
partial GHD” [7] was found. However, with the progressive
improvement and higher usage of imaging studies, cases of
the incidence of hydrocephalus in Crouzon syndrome are
not uncommon. From Proudman’s large study of central
nervous system imaging in Crouzon syndrome performed in
South Australia [8], ventriculomegaly was present in 51% of
available reviewed cases. Most of those taken with follow-up
computed tomographic scans were nonprogressive, even in
cases of severe ventriculomegaly (hydrocephalus). There are
various theories about the mechanism of hydrocephalus. In
Noetzel’s study [9], he suggests that hydrocephalus occurs
secondary to the defective formation of the cranium, so it
is reasonable that in many cases the hydrocephalus is non-
progressive. Most ventriculomegaly in Crouzon syndrome is
asymptomatic and does not necessitate any treatment, unless
there is a clear evidence of significantly raised intracranial
pressure. Fronto-orbital advancement and shunt system are
treatments of choice [8].
In our report case, GHD may have resulted in this
patient’s growth retardation, which is not a common
finding in Crouzon syndrome. Does GHD result from
hydrocephalus? There have been a few reports of endocrine
disorders in children with shunted hydrocephalus, such as
sexual precocity [10, 11] or decreased basal levels of GH
and IGF-1 [12]. Increased intracranial pressure has been per-
ceived as a possible cause of pituitary dysfunction. In a series
of papers by Lo¨ppo¨nen et al. [13–16], the growth pattern




Figure 3: MRI revealed obstructive hydrocephalus of both lateral
ventricles, shallow orbits, and cerebellar tonsil herniation (Chiari
I malformation). Pituitary height was 5.6 mm in midsagittal T1-
weighted spin-echo MRI.
of 114 children with shunted hydrocephalus was analyzed.
It was characterized by slow linear growth in prepuberty,
accelerated physical maturation during puberty, and reduced
final height [13]. This has also been shown to be associated
with accelerated pubertal development in both boys and girls
[14]. Furthermore, they studied these patients’ serum growth
hormone, plasma IGF-1, and IGFBP-3 concentrations. They
concluded that reduced growth hormone secretion may
contribute to the pattern of slow linear growth and reduced
final height observed in these patients [15]. Since there
was an association with growth hormone, Lo¨ppo¨nen et
al. designed a study performing radiography of the sella
turcica, MRI of the pituitary gland, and pituitary hormone
stimulation tests in a subgroup of this large series (54 out of
114) to assess pituitary size and functional capacity [16]. The
results indicated that children with shunted hydrocephalus
had an increased pituitary size on average. About one-
third of these patients had signs of reduced GH secretion
and a significantly lower pituitary height, which probably
contributed to their poor linear growth. Increased pituitary
size was associated with enhanced gonadotrophin secretion,
which may result in early puberty in children with shunted
hydrocephalus.
Another review article about disorders of growth and
puberty in children with nontumoral hydrocephalus had
similar results [17]. They concluded that central early
puberty was the most frequent endocrine disorder in 21 out
of 31 patients. In their cases, short stature was frequently due
to meningomyelocele and rarely to GH deficiency.
In our case, the pituitary height in MRI was not smaller
than normal for his age, but an interruption of the pituitary
stalk was found. He was only found to have GHD but
no signs of early puberty. His hydrocephalus and Chiari I
malformation were stationary except for the shallow orbits
becoming more prominent. He had severe proptosis but his
visual acuity was normal. Although Chiari I malformation
could also cause headache or dizziness [18], his dizziness
might have been caused by severe IDA, since the symptoms
disappeared after anemia correction. The results of HGH
treatment were not satisfactory during the first half year,
but became better after IDA had been corrected. Therefore,
besides the compliance and method of HGH injection, other
underlying diseases should be considered and treated if the
therapeutic eﬀect is not as expected.
Is there any association between GHD and Chiari I mal-
formation? Tubbs et al. reported a study which showed that a
small group of children with GHD had small posterior fossa,
which was similar to the features of Chiari patients [19]. They
hypothesized that GHD might lead to Chiari I malformation
through the underdevelopment of the posterior fossa. In
one of their following case studies [20], by presenting the
case of 3 brothers, 2 with GHD and Chiari, and one with
neither, they provided evidence of this. Therefore, it would be
interesting to see if HGH therapy leads to the improvement
of Chiari malformation. Although surgery is not necessary
in our case so far, we hope to see HGH therapy contributes
to improvement of Chiari malformation by the annual MRI
survey.
The diagnosis of Crouzon syndrome is usually made
by the patients’ clinical signs, including acrocephaly, orbital
proptosis, midfacial hypoplasia with “parrot-beak” nose,
short upper lip, high narrow palate, narrowly spaced teeth,
and prognathism [21]. To date, most patients have been
shown to carry mutations of the FGFR2 gene [22]. In Chi-
ang’s mutation analysis of Crouzon syndrome in Taiwanese
patients, three of the 12 patients carried the Cys342Arg
mutation, which is the most frequent mutation found in
Taiwanese patients. The second most common, as in our
case, is the Cys278Phe mutation [23]. Molecular analysis
of the FGFR2 gene can help to confirm and classify the
diagnosis of craniosynostosis syndrome.
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